CPA
INBX icon

Capital Performance Advisors’s Inhibrx INBX Stock Holding History

Capital Performance Advisors’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-61
Closed -$955 – 1350
2024
Q3 		$955 Buy
+61
New +$857 ﹤0.01% 1930

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SC
Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Performance Advisors's INBX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Inhibrx (INBX) in Q4 2024, closing a stake of 61 shares — an estimated $955 sold.

Capital Performance Advisors first reported a position in INBX in Q3 2024 and held it in 1 quarter. The position peaked at $955 in Q3 2024. 101 funds tracked by Wall St. Rank hold INBX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Inhibrx position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 61 Inhibrx shares in Q4 2024, an estimated $955.
  • Capital Performance Advisors first reported a position in Inhibrx in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Inhibrx position peaked at $955 in Q3 2024.
  • 101 funds tracked by Wall St. Rank held Inhibrx as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.